Very nice results, confirming EXTEND from @ChadTangMD et al. MDT has added value over systemic Tx alone. #ASTRO26. @RKSayyid these results have to be added to Wolverine!

Dr Buyyounouski @StanfordRadOnc w 5y AE outcomes after hypofrac vs standard post-op RT for #ProstateCancer in @NRGonc GU003 Outcomes are encouraging. Do we need to wait for 13y outcomes in light of Wisconsin study? @ASTRO_org #ASTRO26

SO, the GU-003 data could continue to look worse with time as f/u matures, because of the DOSE ESCALATION. 📉 These data don’t kill hypofrac, they just strengthen the case for 52.5 Gy/20 fx, as used in RADICALS, to be preferred hypofrac postop regimen—shorter tx **without the dose escalation** used in GU003. #ASTRO26 #ProstateCancer   #ASTRO26 #Pcsm #RadOnc

New #ASTRO2026 data from @NRGOnc /RTOG 0534 SPPORT 🔬🧬 presented by Shuang (George) Zhao @UTMDAnderson. PAM50 Luminal B = both prognostic & predictive of benefit from postop ADT. 📈 5-y FFP benefit: 31% vs 10% (p-int=.01) 🎯 10-y MFS: 20% vs -3% (p-int=.05) #Pcsm @Astro_org

Posthoc analysis of RTOG 0534 independently validates NRG-GU006: PAM50 LumB predicts hormone benefit after prostatectomy (FFP +31% in lumB vs +10% non-LumB, P-int=.01; MFS +20% vs −3%, P-int=.05). PAM50 should be SOC and has higher level evidence than Oncotype for breast cancer! #ASTRO26 @urotoday @Decipher_VCYT @AmarUKishan @DrChoueiri @angela_jia_ @jamesbyu @HimanshuNagarMD @TylerSbrt @SbrtSean @MutlaySayan

I’ve been saying this for years… Now we have randomized data. GETUG P05: brachytherapy boost vs dose-escalated EBRT in intermediate-risk prostate cancer. Oncologic outcomes similar but far more toxicity with brachy. #ASTRO26 #ProstateCancer @ASTRO_org @NehaVapiwala @AmarUKishan @DrAndrewLoblaw @seanmmcbride @HimanshuNagarMD @TylerSbrt @seanmmcbride @alison_tree @Soum_Roy_RadOnc @NicholasZaorsky @angela_jia_

Microwave ablation versus stereotactic body radiotherapy for oligometastatic colorectal liver metastases (LAVA-CRLM): a prospective, randomised, phase II trial thelancet.com/journals/lanep…

Radiotherapy after surgery halves risk of recurrence in a type of brain tumour that can often grow back, trial shows. Find out more in The Lancet: spkl.io/60137TUFS #EANO2026

Nice article in the Red @IJROBP on lymphopenia following different palliative RT dose/fractionation schedules by @LeilaTchelebi and colleagues. Looks like 8Gy/1fr is associated with less lymphopenia than 20/5 and 30/10, and exploratory analysis hinted to better OS with less lymphopenia. Hypothesis generating, but increasingly important in the Immunotherapy era. Food for thought! @jryckman3 @adib_elio @5_utr @KaramLab @rweichselbaum redjournal.org/article/S0360…

Could “more bladder filling” actually make prostate radiotherapy harder for both patients and treatment teams?🎯 practicalradonc.org/article/… Excessive Bladder Filling at Simulation Correlates with Longer Treatment Times, More Interruptions, and Inferior Patient Experiences During #ProstateCancer Radiotherapy☢️ This study examined whether excessive bladder filling during prostate radiotherapy affects treatment efficiency and patient experience. ➡️Among 211 patients, bladder diameters >10 cm were associated with longer treatment times, more table interruptions, increased worry, and greater frustration. ➡️Importantly, coaching patients to reduce bladder size was feasible and successfully achieved in all 20 coached patients, resulting in shorter treatment times. ✅The findings support personalized bladder-filling guidance during prostate radiotherapy. @ASarafMD2, @jonathan_leeman, @DrPaulNguyen, @MoningiShalini @OncoAlert 🚨 #LPCCC27 @Silke_Gillessen @AOmlin @ProfKHerrmann @weoncologists

Now published in Practical Radiation Oncology: @ASTRO_org's first clinical practice guideline on radiation therapy for bladder cancer! The guideline supports trimodal therapy as a curative, bladder-preserving option for appropriately selected patients with muscle-invasive bladder cancer and clarifies radiation’s role after surgery and in advanced disease. Multidisciplinary care and shared decision-making are central throughout. It was a privilege to co-chair this effort with Leslie Ballas and work with an exceptional multidisciplinary task force, our patient representative, and ASTRO staff. Thank you all for your expertise, collaboration, and dedication to improving bladder cancer care. A tremendous team effort! Read more: bit.ly/4rcR77D @ESTRO_RT @Uroweb #RadiationOncology #BladderCancer #OncoNews #RadOnc #PracticalRO #GUOncology

Prostate cancer treatment is evolving faster than ever — but are our clinical pathways keeping pace? 🧬 Article sciencedirect.com/science/ar… EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2026 Update: Treatment of Relapsing and Metastatic #ProstateCancer The 2026 EAU-EANM-ESTRO-ESUR-ISUP-SIOG prostate cancer guidelines incorporate evidence published from 2023–2025 and strengthen recommendations across relapsing, metastatic hormone-sensitive, and castration-resistant disease. ➡️ Risk stratification can inform salvage treatment, while therapeutic options continue to expand through AR pathway inhibitors, metastasis-directed therapy, PARP inhibitors, combinations, and PSMA-based treatments. ✅ The update highlights increasingly multidisciplinary management, while acknowledging that recommendations may vary with healthcare-system resources, reimbursement, and treatment access. @Tilki_De, @roodvdb, @peterchiu_uro, @deberli, @adina_epure, @andrea_farolfi, @fontev1, @GGandaglia, @Silke_Gillessen, @nicgrivas, @AnnHenryIP, @LeendersGeert, @elinares13, @jan_oldenburg, @MPWRoberts, @AshwinUrol, @IvoSchootsNL, @OncoAlert 🚨 #LPCCC27 @Silke_Gillessen @AOmlin @ProfKHerrmann @weoncologists

1/🎯 Our short communication out in @RO_GreenJournal: What happens when you integrate Lu-177-PSMA-617 (LuPSMA) with metastasis-directed EBRT ☢️ in metastatic prostate cancer? We looked at 88 patients who received both. Here's what we found 🧵 doi.org/10.1016/j.radonc.202…

Dr. Chad Rusthoven at #WCLC26 presents results from SWOG S1827, the phase III MAVERICK study exploring the benefit of PCI in pts with SCLC. Historic studies before the era of MRI surveillance showed a decrease in brain metastases with PCI and an improvement in OS but recent ES-SCLC studies called the OS improvement into question. MAVERICK looks at both LS and ES disease - note primary endpoint here is cognitive failure free survival (time to cognitive failure or death) with OS as a key secondary.

Hot of the press in @TheLancet Imaging & Theranostics. the Swiss Lu-177 PSMA-I&T Registry Study. 333 patients. Prospective. Real world. Complements randomised data.

Morning coffee is linked to a longer life.

🚨 Exercise improved QoL for patients on ADT for #prostatecancer & it costs less per QALY than most cancer drugs the NHS funds 🚨 🏋️‍♂️@TheLancetOncol STAMINA trial: 👥 700 men on ADT, median age 71.6, 34% metastatic, 19% on ARPI or chemo 📊 Randomized 5:4 vs an ACTIVE comparator: optimised usual care w/ clinician training and behavioural prompts 💊 12 mo supervised aerobic + resistance exercise in community gyms, dietary advice, behavioural support, free membership ✅ FACT-P +4.5 (p=0.0004), FACT-G +3.7, above the >3 point clinically important threshold ✅ Fatigue (FACIT-F) +1.9 (p=0.0068) ✅ £13,920 to £19,077 per QALY. Median ICER for NICE-approved oncology drugs: £30,000 ⚠️ Open label PROs, 97% of pts White, fatigue effect at the edge of MCID, physical outcomes unchanged ⚠️ 3 intervention-related SAEs, all recovered 🎯 This beat an already-enhanced control, in a population including metastatic pts, delivered through community gyms at scale. 👉I think many of us have been telling patients for years to exercise while on ADT to reduce side effects, now we have trial-grade data! *The figure in this post is not from the paper, based on tabular data!!! 🔗 doi.org/10.1016/S1470-2045(2… @AmerUrological @UroOnc @SUO_YUO @PCFnews @urotoday @UrologyTimes @CaPsurvivorship

⏰ LAST CALL: Extended deadline closes on 15 September! Advance your career in prostate cancer care with the 3rd cohort of the CAS-Pr programme, developed by ESO and @USI_university. • 16-month part-time academic course • 6 online modules & 3 in-person seminars • Full tuition scholarship available via ESO College 👥 Chairs: A. Gallina, @Silke_Gillessen, @BarbaraJereczek, @UrsulaVogl 👉 Apply today: bit.ly/CASProstate

Three-dimensional treatment planning and target volume definition of tendinitis and bursitis - Consensus statement of the International Benign Target Volume Group (IBTVG) #radonc #ldrt redjournal.org/article/S0360…

ASTRO is proud to be a founding supporter & part of the organizing committee for World Radiotherapy Awareness Day (WRAD). Monday, Sept 7 is the day & we hope our radiation oncology community will help spread the word about how RT is used to cure & treat cancers & other conditions. Thank you to ASTRO President @NehaVapiwala for speaking on behalf of ASTRO's 10,000 members. Together we are #OneVoiceForRadiotherapy